SCHEMBL1776965

SCHEMBL1776965

CC(C)(C)C1(N2CCN(C(=O)O)[C@@H](C(=O)N3CCN(c4ccc(Cl)c(Cl)c4)CC3)C2)CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
SMN1; SMN2 Q16637 6/20 0.42
HTT P42858 4/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GFER P55789 1/20 0.40
RAB9A P51151 1/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38
NOTUM Q6P988 1/20 0.38
PANK3 Q9H999 1/20 0.37
CCR1 P32246 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781013 0.99 MAPT (0.43) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL4587250 0.81 MAPT (0.52) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL1779615 0.81 MAPT (0.48) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL1779616 0.81 MAPT (0.48) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL1778567 0.79 MAPT (0.48) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL1778569 0.79 MAPT (0.48) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL4589136 0.77 MAPT (0.44) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL4587969 0.76 MAPT (0.45) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL1778139 0.76 MAPT (0.46) MAPTSMN1; SMN2HTTMAPK1ALDH1A1
SCHEMBL4588286 0.74 MAPT (0.49) MAPTSMN1; SMN2HTTMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943768-B2 Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases ASTRAZENECA AB (SE) 2011-05-17 US disclosed